Genetic variation in CACNA1C, which codes for the L-type calcium channel (LTCC) Ca v 1.2, is associated with clinical diagnoses of bipolar disorder, depression and schizophrenia. Dysregulation of the mesolimbic-dopamine (ML-DA) system is linked to these syndromes and LTCCs are required for normal DAergic neurotransmission between the ventral tegmental area (VTA) and nucleus accumbens (NAc). It is unclear, however, how variations in CACNA1C genotype, and potential subsequent changes in expression levels in these regions, modify risk. Using constitutive and conditional knockout mice, and treatment with the LTCC antagonist nimodipine, we examined the role of Cacna1c in DA-mediated behaviors elicited by psychomotor stimulants. Using fast-scan cyclic voltammetry, DA release and reuptake in the NAc were measured. We find that subsecond DA release in Cacna1c haploinsufficient mice lacks normal sensitivity to inhibition of the DA transporter (DAT). Constitutive haploinsufficiency of Cacna1c led to attenuation of hyperlocomotion following acute administration of stimulants specific to DAT, and locomotor sensitization of these mice to the DAT antagonist GBR12909 did not reach the same level as wild-type mice. The maintenance of sensitization to GBR12909 was attenuated by administration of nimodipine. Sensitization to GBR12909 was attenuated in mice with reduced Cacna1c selectively in the VTA but not in the NAc. Our findings show that Cacna1c is crucial for normal behavioral responses to DA stimulants and that its activity in the VTA is required for behavioral sensitization. Cacna1c likely exerts these effects through modifications to presynaptic ML-DA system function.
A genetic component substantially influences risk for developing mood disorders. Genome-wide association studies have identified genetic variants in CACNA1C as a risk factor for the development of bipolar disorder and depression, as well as schizophrenia (Bhat et al. 2012; Ferreira et al. 2008; Green et al. 2010 Green et al. , 2012 Hamshere et al. 2013; Liu et al. 2011; Moskvina et al. 2009; Nyegaard et al. 2010; Ripke et al. 2011 Ripke et al. , 2013 Ripke et al. , 2014 Sklar et al. 2008 Sklar et al. , 2011 Smoller et al. 2013) . Despite the significance of this human genetic finding, the mechanism by which genetic variants in CACNA1C modify the risk of developing a psychiatric illness remains largely unknown. CACNA1C codes for the 1C subunit of the Ca v 1.2 channel, which contains the voltage sensor, the conduction pore and is a primary target for both drugs and second messengers acting on L-type calcium channels (LTCCs) (Catterall et al. 2005) . As the identified single nucleotide polymorphisms (SNPs) are found in an intronic (non-protein coding) region of CACNA1C, mechanisms whereby genetic changes modify risk are likely via altered levels of CACNA1C in specific regions of the brain. Studies have supported this, showing that the CACNA1C risk allele is associated with increased mRNA expression of CACNA1C in the human post-mortem dorsolateral prefrontal cortex and in induced human neurons (Bigos et al. 2010; Yoshimizu et al. 2014) . Decreased expression of CACNA1C was also identified in the human post-mortem cerebellum and parietal cortex samples (Gershon et al. 2014) and in an analysis of human brain available from multiple sources (Roussos et al. 2014) .
There is evidence that Cacna1c is involved in regulation of mesolimbic-dopamine (ML-DA) system-mediated behaviors in rodents, including reinstatement of cocaine seeking after LTCC activation in the nucleus accumbens (NAc) (Anderson et al. 2008) , and LTCC-mediated changes in calcium currents in the NAc following repeated cocaine administration (Zhang et al. 2002) . In rats, sensitization to amphetamine is associated with an increase in Cacna1c mRNA and protein in the ventral tegmental area (VTA) (Rajadhyaksha et al. 2004) . Although there is mounting evidence that normal Ca v 1.2 function is important in ML-DA system-mediated behaviors, the specific neural substrates through which it acts are largely unknown. The ML-DA system function modulation by Ca v 1.2 may be related to the pathophysiology of psychiatric disorders linked to genetic changes in CACNA1C. Dysregulation of the ML-DA system is implicated in the expression of endophenotypes of bipolar mania and schizophrenia, as well as depression (Basar et al. 2010; Grace 2016; Nestler & Carlezon 2006; Ryding et al. 2008; Salamone et al. 2016; Whitton et al. 2015) . Drugs that acutely increase release, or reduce reuptake of DA result in mania and psychosis phenotypes in humans (Anand et al. 2000; Drevets et al. 2001; Leyton et al. 2002; Lieberman et al. 1987; Murphy et al. 1971) . Antipsychotics, as well as other treatments that impede DAergic neurotransmission, diminish mania, as well as psychotic symptoms, in humans (Creese et al. 1976; McTavish et al. 2001; Perlis et al. 2006) .
We previously found that D-amphetamine-induced hyperlocomotion was attenuated in mice lacking one copy of Cacna1c (Dao et al. 2010) . Here, we further characterized the role of that decreased Cacna1c function on ML-DA system-mediated behaviors and hypothesized that stimulant-induced DA release and/or reuptake would be modulated by Cacna1c levels. Using rodent models of reduced Cacna1c function both globally and in specific brain regions, we show that Cacna1c modulates DA-dependent stimulant-induced locomotor activity and sensitization. Additionally, we used fast-scan cyclic voltammetry (FSCV) to directly examine the role of Cacna1c in subsecond DA release and reuptake, finding that reduced Cacna1c leads to an attenuated response to DA reuptake blockers following stimulant administration. Therefore, we show that Cacna1c modulates DA reuptake and that its function in the VTA is necessary for the development of stimulant-induced sensitization.
Materials and methods

Animals
Male and female Cacna1c haploinsufficient (Cacna1c +/− ) founder mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) as previously described (Dao et al. 2010) . Cacna1c +/+ and Cacna1c
mice were the product of in-house breeding of Cacna1c +/− males generated in our own colony and WT C57BL/6 females obtained from Jackson Laboratories and were backcrossed for at least 10 generations (Dao et al. 2010) . We previously showed that Cacna1c +/ − mice have ∼50% decreased Ca v 1.2 protein levels and ∼30% decrease in mRNA levels in the hippocampus, as well as decreased L-type voltage gated calcium channel (L-VGCC) current density in CA1 compared with their wild-type littermates (Dao et al. 2010; Zanos et al. 2015) . We previously found that there were baseline differences in locomotor activity in female, but not in male, Cacna1c haploinsufficient mice (Dao et al. 2010) , consistent with an overall decrease in locomotor activity observed in Cacna1c haploinsufficient mice across 30 inbred mouse strains (Sittig et al. 2016) . We therefore only used male animals for experiments, as it would have been difficult to interpret any results obtained using female haploinsufficient mice, owing to the baseline difference in locomotor activity. In the conditional Cacna1c knockout mouse line, exons 14 and 15 of Cacna1c are excised in the presence of Cre, leading to a premature stop codon and removing all known functional significance of the resulting protein (Jeon et al. 2010) . A line of conditional Cacna1c knockout mice (Jeon et al. 2010) were also bred on a C57BL/6 background and maintained as homozygous for the floxed allele. All mice used were group-housed males between 8 and 20 weeks of age at the time of behavioral testing and between 10 and 14 weeks at the time of testing in FSCV and tissue collection for immunoblotting. Cacna1c +/+ and Cacna1c +/− mice used in experiments were littermates, and likewise AAV-Cre-Green fluorescent protein (GFP)-and AAV-Cre-injected mice from the conditional Cacna1c knockout mouse line were littermates. Mice were tested during the light phase. All experimental procedures were approved by the University of Maryland Animal Care and Use Committee and were conducted in full accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Fast-scan cyclic voltammetry
Carbon fiber microelectrodes were prepared as previously described (Cheer et al. 2004) . Stimulation electrodes were made by twisting electrodes (Plastics One, Roanoke, VA, USA) and cutting ends evenly. Ag/AgCl reference electrodes were made from 0.5 mm Ag wire (Sigma-Aldrich, St. Louis, MO, USA) through electrolysis in HCl (Sigma-Aldrich).
Voltammetry experiments were performed based on a protocol previously described (Loewinger et al. 2012) . Animals were anesthetized with urethane (1.5 g/kg, i.p.) and placed in a stereotaxic apparatus. Holes were drilled for the carbon fiber microelectrode to access the NAc (+1.2 AP, +1.1 ML from bregma), for a bipolar stimulating electrode to access the VTA (−3.1 AP; +0.7 ML from bregma) and for an Ag/AgCl reference electrode placed in the contralateral hemisphere. Once positioned, the carbon fiber electrode was held at −0.4 V in reference to the Ag/AgCl electrode. Cyclic voltammograms were collected at 10 Hz by ramping up to +1.3 V and back in a triangular fashion at 400 V/second. Stimulation, voltage and data collection were controlled through the Tarheel Echem suite (University of North Carolina, Chapel Hill, NC, USA). After experimentation, changes in electrical current were converted to DA concentration changes via post-calibration of the carbon fiber electrodes to a known concentration of DA.
To determine DA release and reuptake following DA transporter (DAT) blockade, peak amplitude and decay rates following a 1-second, 60-Hz, 300-A stimulation were recorded following a 5-ml/kg i.p. saline injection and at 21 min following an i.p. injection of GBR12909 (16 mg/kg) (Sigma-Aldrich). To determine decay rate, % of peak DA concentration vs. time plots were exported to Prism version 5 (Graph Pad, La Jolla, CA, USA). One-phase decay regression lines were fit to the data and software generated values were determined for the decay constant tau. Tau indicates the time at which DA levels have dropped to 37% of the maximum, and was used as a measure of DA reuptake (Yorgason et al. 2011) .
Western blots
Western blots were performed using a previously published protocol (Gould et al. 2004) . Immediately following decapitation the brain was sectioned into 1.0-mm slices using a matrix (ASI Instruments, Warren, MI, USA) and the NAc was obtained using a 1.5-mm punch (Miltex, Inc., York, PA, USA). The NAc tissue samples from homozygous DAT knockout (DAT −/− ) and wild-type mice (DAT +/+ ) (Giros et al. 1996) were obtained from Dr Sara Jones. Samples were homogenized in Radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors (Sigma-Aldrich). The homogenates were centrifuged at 12 000 g for 20 min at 4 ∘ C. Protein concentrations were determined using a bicinchoninic acid assay (Peirce Biotechnology, Inc., Rockford, IL, USA). For immunoblotting, 1 μg of each sample was loaded on to a 4-12% Bis-Tris gel (Life Technologies, Grand Island, NY, USA) and transferred onto Polyvinylidene difluoride membranes (Life Technologies). Membranes were incubated overnight at 4 ∘ C with rat anti-DAT at a 1:4000 dilution (Millipore MAB369) and rabbit anti-GAPDH at a 1:40 000 dilution (Millipore #5174) (EMD Millipore, Billerica, MA, USA). Membranes were washed and incubated with horseradish peroxidase-tagged anti-rat (Cell Signaling Technology Inc., Danvers, MA, USA) and anti-rabbit (KPL, Inc., Gaithersburg, MD, USA) secondary antibodies, visualized using a chemiluminescence reaction (Clarity TM Western ECL Substrate, Bio-Rad Laboratories, Inc., Hercules, CA, USA) and quantified using densitometry (Image J, National Institutes of Health, Bethesda, MD, USA; Schneider et al. 2012) . Results are expressed as relative optical density with DAT values normalized to GAPDH.
Virus injections
Mice were anesthetized with isoflurane and stereotaxically received an injection of 0.7 μl AAV-CMV-Cre-GFP or AAV-CMV-GFP (UNC Vector Core, Chapel Hill, NC, USA) bilaterally into the NAc (+1.6 anterior/posterior, +1.5 lateral and −4.4 dorsal/ventral, 10 ∘ angle) or the VTA (−3.2 anterior/posterior, +1.0 lateral and −4.6 dorsal/ventral, 7 ∘ angle). Injections were performed at a rate of 0.1 μl/min and the needle was left in place for 10 min prior to being removed. Following Reduced Cacna1c attenuates MA-DL system function injections, a 2-week recovery period was given prior to experiments. Following experiments, mice were euthanized. Immediately following decapitation the brain was sectioned into 1.0-mm slices using a matrix (ASI Instruments) and placed in cold phosphate-buffered saline (PBS). Brain slices were then visualized through a fluorescent microscope (Leica Microsystems GmbH, Wetzlar, Germany). Mice that did not show fluorescence bilaterally in the targeted structures were excluded from the results. In the NAc-injected group, this included nine mice, and in the VTA-injected group this included six mice.
qPCR and immunohistochemistry
The mRNA was extracted from 1.5-mm tissue punches from AAV-injected mice. Tissue samples were homogenized in RNAzol RT (Sigma-Aldrich) using BashingBead lysis tubes (Zymo Research Corporation, Irvine, CA, USA) in a disrupter genie (Scientific Industries, Bohemia, NY, USA) for 10 min at 955. The mRNA was isolated and DNAse treated using the Directzol RNA Mini Prep Kit, according to manufacturer's directions (Zymo Research Corporation). Using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc.), total RNA was reverse transcribed into cDNA. Real-time polymerase chain reaction (PCR) was conducted using a SensiFast SYBER Lo-ROX Kit (Bioline, Taunton, MA, USA) in a 15-μl reaction. A primer pair for the target gene, Cacna1c (5
, as well as the control genes
′ -AGAAACTGCTGCCTCACATC-3 ′ ) were used (Integrated DNA Technologies, Coralville, IA, USA). The PCRs were run on a ViiA 7 Real-Time PCR System (Life Technologies) with a reaction volume of 15 μl and an annealing temperature of 60 ∘ C. ViiA 7 software (Life Technologies) was used to determine Ct values. Cacna1c levels were normalized to the mean of Tfrc and Rplp0, and fold difference was determined using the 2 −ΔΔCt method (Livak & Schmittgen 2001) . Three mice that had Cacna1c expression levels that were two standard deviations from the mean in the NAc were excluded from the results.
Microscopy
Coronal sections (30 μm) of paraformaldehyde perfused brains were cut in a cryostat and placed in 1× PBS. Sections were then blocked in 20% Triton-X-100 (Sigma-Aldrich) for 30 min and incubated overnight with primary antibody (Chicken anti-GFP, 1:4000, Aves Labs, Inc., Tigard, OR, USA) at room temperature. Sections were then washed and incubated in secondary antibody for 2 h at room temperature (Donkey anti-Chicken Alexa-488 Green, 1:1000, Life Technologies), mounted and cover slipped. After drying, sections were visualized under a confocal microscope (Olympus Fluoview, Shinjuku-ku, Tokyo, Japan) and images were obtained.
Acute locomotor response to stimulants
Mice were habituated to an open field (50 × 50 cm 2 ; illuminated at 30 lux) for 30 min, after which they received an injection of D-amphetamine (2 mg/kg i.p.), cocaine (10 mg/kg s.c.), GBR12909 (16 mg/kg i.p.) or MK-801 (0.3 mg/kg i.p.) (Sigma-Aldrich) and were returned to the open field for an additional 45 (D-amphetamine and cocaine) or 90 min (GBR12909 and MK-801). Doses and route of administration were based on those established previously in the literature as resulting in a moderate hyperlocomotor response, in order to allow a further increase to be possible without inducing stereotypic behaviors. (Hirabayashi et al. 1991; Liljequist et al. 1991; McNamara et al. 2006; Young et al. 2010) . All compounds were dissolved in 0.9% saline on the day of testing. Distance traveled was assessed using TopScan tracking software (CleverSys, Inc., Reston, VA, USA).
Sensitization to GBR12909
GBR12909, unlike amphetamine and cocaine, works specifically through blockade of the DAT (Andersen 1989; Heikkila & Manzino 1984) . GBR12909 was therefore used to specifically evaluate activity at the DAT, eliminating confounding effects of drugs such as amphetamine or cocaine that affect other monoamine transporters. Mice were tested for GBR12909-induced locomotor sensitization in an open field (50 × 50 cm 2 ) illuminated at 30 lux. During the first 3 days of testing, mice were habituated to the open field following saline injections. Mice were then administered 16 mg/kg GBR12909 (Sigma-Aldrich) over six consecutive sensitization days. In experiments where nimodipine was used, mice were habituated to the open field following saline injections for three (4 mg/kg) or four (6 mg/kg) days and on the fourth (or fifth) day were given a nimodipine (Alexis Biochemicals, San Diego, CA, USA) injection [4 or 6 mg/kg, suspended in 20% dimethyl sulfoxide (DMSO; Sigma-Aldrich), 1.5% Tween-80 (Sigma-Aldrich) and saline] or vehicle. Over six consecutive sensitization days, mice received 4 or 6 mg/kg nimodipine or vehicle once per day, were returned to the home cage and after 30 min received 16 mg/kg GBR12909 and were placed in the open field. In a protocol based on that used by Giordano et al. (2010) , the mice in the experiment using 4 mg/kg nimodipine were tested again at 1, 3 and 4 weeks after the last sensitization day During the 4-week test, half of the mice previously treated with nimodipine received a vehicle injection and half of the mice previously treated with vehicle received 4 mg/kg nimodipine prior to administration of GBR12909. The low volume of DMSO included in the nimodipine vehicle did not lead to any locomotor changes in control experiments. All sessions were 1 h, and distance traveled was analyzed using Topscan tracking software (CleverSys, Inc.).
Statistical analysis
Statistical analyses were performed using GraphPad Prism Version 5 (GraphPad Software). The statistics used were two-tailed t-test or repeated measure two-way analysis of variance (ANOVA), either paired or unpaired depending on the experimental design, and post hoc comparisons utilized the Bonferroni method. The results of final (4 week) challenge using 4 mg/kg nimodipine were analyzed with a planned comparison t test. Data are reported as mean ± SEM and P < 0.05 was considered significant.
Results
DA release and reuptake in Cacna1c
+/+ and Cacna1c +/− mice Using FSCV, we assessed DA release and reuptake in the NAc following electrical stimulation in the VTA of Cacna1c +/+ and Cacna1c +/ − mice following saline and GBR12909 administration (Fig. 1a) . Administration of GBR12909 led to increased extracellular DA concentrations (Fig. 1a,b ) and slowed DA reuptake compared with saline administration (Fig. 1a,c ). This is indicated by an overall significant increase in DA following a 300-A stimulation ( Fig. 1b ; F 1,10 = 11.82, P < 0.01) and increased decay rate (tau; Fig. 1c ; F 1,10 = 8.71, P < 0.05). Additionally, there was a significant overall effect of genotype on tau following GBR12909 administration ( Fig. 1c ; F 1,10 = 5.65, P < 0.05). There was no effect of genotype on DA levels (F 1,10 = 0.36, P = 0.56), and no significant genotype × drug interaction for increase in DA ( Fig. 1b ; F 1,10 = 0.31, P = 0.59) or increase in tau ( Fig. 1c ; F 1,10 = 1.60, P = 0.23). While Cacna1c +/+ and Cacna1c +/ − mice had similar levels of DA reuptake following saline administration, an exploratory Bonferroni posthoc analysis indicated that Cacna1c +/+ mice had a significantly higher tau value compared with Cacna1c +/ − mice only following GBR12909 administration (P < 0.05), indicating that Cacna1c haploinsufficiency is associated with attenuated effects of GBR12909 on DA reuptake (Fig. 1c) . (n = 6/group) led to an overall significant increase in DA release in both Cacna1c +/+ and Cacna1c +/− mice (P < 0.01). (c) Administration of GBR12909 led to an overall significant increase in tau (P < 0.05), and an overall significant effect of genotype on DA reuptake (P < 0.05). (d, e) There was no significant effect of genotype on DAT protein levels in the NAc (P = 0.33) as measured by immunoblot. n = 8/group. *P < 0.05, **P < 0.01. hyperlocomotion was assessed in Cacna1c +/+ and Cacna1c +/ − mice. There were no significant baseline differences between genotypes during a 30-min habituation in the open field (Fig. 2) . Compared with Cacna1c +/+ mice, Cacna1c +/ − mice displayed a significantly lower locomotor response following administration of D-amphetamine ( Fig. 2a ; F 1,14 = 8.12, P < 0.05) and cocaine ( Fig. 2b ; F 1,29 = 8.31, P < 0.01). As both of these stimulants have non-specific actions on multiple monoamine neurotransmitters, we also assessed hyperlocomotion following administration of the specific DAT inhibitor GBR12909. There was a significant difference in hyperlocomotor response to GBR12909 in Cacna1c +/ − mice compared with that observed in Cacna1c +/+ mice ( Fig. 2c ; F 1,14 = 4.60, P < 0.05). In contrast, there was no significant difference in hyperlocomotor activity between genotypes following administration of the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 ( Fig. 2d ; F 1,13 = 0.92, P = 0.3546). Following administration of all psychostimulants, two-way analyses of variance (ANOVAs) further showed that there was a significant overall effect of day [D-amphetamine (Fig. 2a) F 8,112 = 4.99, P < 0.05; cocaine (Fig. 2b) F 8,232 = 2.96, P < 0.01; GBR12909 (Fig. 2c) F 17,238 = 2.54, P < 0.001; MK-801 (Fig. 2d) F 17,221 = 68.52, P < 0.0001] and a significant interaction between time and genotype following cocaine ( Fig. 2b; F 8 ,232 = 12.68, P < 0.0001) and GBR12909 ( Fig. 2c ; F 17,238 = 2.01, P < 0.05) administration. There was no significant interaction following D-amphetamine ( Fig. 2a; F 8,112 = 0.72, P = 0.67) or MK-801 ( Fig. 2d; F 17 ,221 = 0.49, P = 0.96) administration.
DAT protein levels in Cacna1c
Sensitization to GBR12909 in Cacna1c
+/+ and Cacna1c +/− mice Compared with Cacna1c +/+ mice, Cacna1c +/ − mice displayed a different hyperlocomotor activity in response to the specific DAT inhibitor GBR12909, which was maintained after repeated administration. There was no significant difference in baseline locomotor activity during the habituation period ( Fig. 3a; Days 1-3) . However, Cacna1c +/ − mice displayed a reduced hyperlocomotor response to GBR12909 during the sensitization period. A repeated measures two-way ANOVA showed a significant overall effect of day ( Fig. 3a; F 5,105 = 26.11, P < 0.0001) and genotype ( Fig. 3a; F 8,21 = 3.32, P < 0.01), with no significant interaction (F 5,105 = 0.29, P = 0.92). The reduced response to GBR12909 in Cacna1c +/ − mice is evident at the beginning of treatment, and is most apparent on the second through sixth day of sensitization ( Fig. 3a; Days 5-9).
Locomotor responses to GBR12909 in mice with a pharmacological blockade of LTCCs
There were no baseline differences during habituation to the open field between groups ( Fig. 3b ; Days 1-4; Fig. 3c ; Days 1-3) or following 6 or 4 mg/kg nimodipine alone (Fig. 3b, Day 5; Fig. 3c ; Day 4). The LTCC antagonist nimodipine (6 or 4 mg/kg) was administered 30 min prior to administration of GBR12909 during the sensitization period. Two-way repeated measures ANOVA showed that there was a significant overall effect of GBR12909 treatment over days (F 5,100 = 23.2, P < 0.0001), an overall effect of In Cacna1c +/+ compared with Cacna1c +/− mice, there is a significant genotype and day interaction on locomotor sensitization to GBR12909 (P < 0.001). Post hoc tests showed a significant difference in locomotor activity on the second through sixth day of GBR12909 administration. (b) There is a significant overall effect of 6 mg/kg nimodipine (Nim) on locomotor sensitization to GBR12909 (P < 0.0001). Post hoc tests showed a significant difference in locomotor activity on the first through sixth day of GBR12909 administration. (c) There is a significant overall effect of 4 mg/kg nimodipine on locomotor sensitization to GBR12909 (P < 0.0001). Bonferroni post hoc tests showed a significant difference in locomotor activity during 1-and 3-week challenges. On Week 4, planned comparisons t-tests showed that mice whose treatment was switched to nimodipine from vehicle or vehicle from nimodipine displayed an attenuation of sensitization or normal sensitization, respectively. *A significant effect of genotype or nimodipine. ***P < 0.001, ****P < 0.0001; n = 11-12/group. nimodipine treatment (F 1,20 = 19.41, P < 0.001) and a no significant interaction (F 5,100 = 0.69, P = 0.63) in mice treated with vehicle or 6 mg/kg nimodipine prior to GBR12909. In mice treated with vehicle or 4 mg/kg nimodipine prior to GBR12909, a two-way repeated measures ANOVA showed a significant overall effect of GBR12909 treatment over days (F 7,154 = 28.59, P < 0.0001), a significant overall effect of nimodipine treatment (F 1,22 = 6.40, P < 0.05) and a significant interaction (F 7,154 = 7.48, P < 0.0001). One week following the last sensitization day, mice were challenged with GBR12909 following treatment with vehicle or 4 mg/kg nimodipine. Bonferroni post hoc tests showed that mice treated with 4 mg/kg nimodipine manifested an attenuated sensitization to GBR12909 compared with vehicle-treated mice ( Fig. 3c ; P < 0.0001). At the 3-week challenge, mice treated with 4 mg/kg nimodipine again manifested attenuated sensitization ( Fig. 3c ; P < 0.0001). At 4 weeks following the initial sensitization procedure, half of the mice previously treated with nimodipine received a vehicle injection and half of the mice previously treated with vehicle received 4 mg/kg nimodipine prior to administration of GBR12909. The other half received the previously assigned treatment. As outlined in Table 1 , planned comparison t-tests showed that mice that were sensitized to GBR12909 with treatment of 4 mg/kg nimodipine, but were given vehicle prior to the 4-week GBR12909 challenge dose displayed no significant difference in locomotor activity from mice that received only vehicle during sensitization and challenge and displayed a significant difference from mice that received nimodipine both during sensitization and prior to the 4-week challenge. Table 1 : Effects of nimodipine on the maintenance of sensitization to GBR12909. Mice were sensitized to GBR12909 following administration of either vehicle (Veh) or 4 mg/kg nimodipine (Nim). At 4 weeks following the initial sensitization procedure, half of the mice previously treated with nimodipine received a vehicle injection and half of the mice previously treated with vehicle received 4 mg/kg nimodipine prior to administration of GBR12909. Planned comparisons t-tests showed that mice whose treatment was switched to nimodipine from vehicle, or vehicle from nimodipine displayed an attenuation of sensitization or normal sensitization, respectively. For all comparisons, df = 10 and n = 6/group Veh-Veh Nim-Nim Veh-Nim Nim-Veh
Veh-Veh
Mice that had been treated previously with vehicle, but that received 4 mg/kg nimodipine prior to GBR12909 on the challenge day showed no significant difference in locomotor activity compared with mice that received only nimodipine injections throughout the study, but manifested attenuated sensitization to GBR12909 compared with mice that received only vehicle during sensitization and challenge, Mice that were treated with nimodipine both during sensitization and prior to the 4-week challenge manifested significantly attenuated locomotor activity compared with mice given only vehicle injections. Furthermore, mice that were sensitized to GBR12909 with treatment of 4 mg/kg nimodipine, but were given vehicle prior to the 4-week GBR12909 challenge dose manifested attenuated locomotor activity compared with mice that were treated with nimodipine during sensitization but were given a vehicle injection prior to the 4-week GBR12909 challenge. These findings suggest that pharmacological blockade of LTCCs at a higher dose leads to an attenuation of locomotor response to GBR12909 similar to that seen in Cacna1c +/ − mice (Fig. 3b) ; however, a lower dose does not result in the acute reduction of GBR12909-induced locomotor activity. Instead, similar to findings of Giordano et al. (2010) , this dose attenuates the maintenance of sensitization, indicating an effect of Ca v 1.2 blockade on sensitization to psychostimulants even in the absence of an acute effect (Fig. 3c) .
Locomotor responses to GBR12909 in mice with a knock down of Cacna1c in the NAc
To determine if the attenuated response to GBR12909 was mediated by Cacna1c in the NAc, sensitization to GBR12909 in mice with virally mediated knockdown of Cacna1c in the NAc was measured. The AAV-Cre-GFP was expressed in the NAc of mice containing a floxed Cacna1c allele. To control for any non-specific effects of the viral injection, control mice received a GFP-only expressing virus. Expression of GFP-tagged Cre in the NAc was confirmed by the use of fluorescence microscopy to visualize GFP expression in neurons in the NAc (Fig. 4a) . Injection of Cre-GFP significantly reduced the level of Cacna1c expression, as measured by quantitative (qPCR), in the NAc by ∼40% [t(17) = 4.43,
In NAc-injected mice, Cre-GFP injection did not lead to baseline differences in locomotor activity during the habituation period compared with GFP-only injected mice (Fig. 4b) . During the sensitization period, there was a significant effect of repeated GBR12909 administration (F 8,96 = 78.44, P < 0.0001), however there was no overall effect of Cacna1c knockdown in the NAc (F 1,12 = 0.054, P = 0.82) and no significant interaction (F 8,96 = 0.43, P = 0.90; Fig. 4b ).
Locomotor responses to GBR12909 in mice with a knock down of Cacna1c in the VTA
Expression of GFP-tagged Cre in the VTA was indicated by the use of fluorescence microscopy to visualize GFP expression in neuronal cells in the VTA (Fig. 4c) . While each injection was visually evaluated, we note that an unavailability of VTA RNA from these samples prevented qPCR analysis of the level of Cacna1c knockdown as had been performed with the NAc samples. Compared with GFP-only injected mice, mice with a VTA knockdown of Cacna1c displayed a significant difference in sensitization to GBR12909, as shown by a significant interaction between day and injection type ( Fig. 4d ; F 8,13 = 3.97, P < 0.001).There was an overall significant effect of day (F 5,65 = 8.54, P < 0.0001), but no overall effect of Cacna1c knockdown in the VTA (F 1,13 = 3.41, P = 0.09).
Discussion
We have shown that Cacna1c haploinsufficient mice manifest an attenuated response to the specific DAT blocker GBR12909, indicating that Cacna1c critically regulates DA terminal function. We also show that mice with one functional allele of the Cacna1c gene manifest a diminished locomotor response to acute and chronic administration of DA elevating psychostimulants, an effect that is replicated with pharmacological blockade of LTCCs. A lower dose of pharmacological LTCC blockade results in attenuation of a maintained locomotor sensitization response, without modifying acute responses to GBR12909. Moreover, reduced levels of Cacna1c in the VTA, but not the NAc, led to attenuation of sensitization to GBR12909. Overall, the data in this study indicate that Cacna1c modulates ML-DA-dependent behavior and DA terminal dynamics, potentially through altered DA reuptake by VTA neurons.
Stimulant-induced blockade of DAT in VTA DA synaptic terminals within the NAc leads to elevated DA levels, slowed DA reuptake and hyperlocomotion in rodents. The hyperlocomotor response induced by acute psychostimulants and sensitization, as well as changes in DA release and reuptake, are widely used to model aspects of mania and psychosis in rodents (Einat & Manji 2006; Nestler & Hyman 2010; O'Donnell & Gould 2007) . In this study, we show that Cacna1c has a role in subsecond DA reuptake kinetics, in particular DA reuptake in VTA neurons projecting to the NAc. While Cacna1c is not expressed exclusively in neurons [Cacna1c expression has also been identified in astrocytic cells (D' Ascenzo et al. 2004; Latour et al. 2003) ], DA reuptake through the DAT in response to stimulant administration occurs primarily through neuronal, and not astrocyte, expressed DAT (Takeda et al. 2002) . GBR12909, unlike amphetamine and cocaine, works specifically through blockade of the DAT (Andersen 1989; Heikkila & Manzino 1984) , giving increased specificity for interpreting the results of DAT inhibition on DA terminal dynamics. Therefore, GBR12909 was used to evaluate specific activity at the DAT, eliminating confounding effects of drugs such as amphetamine or cocaine that affect other monoamine transporters. GBR12909 administration produced the expected decrease in reuptake in wild-type mice; however, in mice with genetically reduced levels of Cacna1c this effect was attenuated.
One mechanism by which the behavioral effects of DAT blockade may be attenuated is through altered levels of the DAT protein. Animal models in which DAT expression level is changed have an altered response to psychostimulants. Amphetamine-and cocaine-induced hyperlocomotion is absent in mice with a mutation in a DAT gene that leads to deletion of DAT (Giros et al. 1996) and cocaine does not slow DA reuptake in DAT knockout mice (Budygin et al. 2002) . Additionally, overexpression of DAT leads to an increase in amphetamine-induced response in mice (Salahpour et al. 2008) . Our Western blot results indicate that the overall level of DAT is not significantly altered in Cacna1c +/− mice, however the finding that GBR12909 does not block reuptake of DA in Cacna1c +/− mice to the same degree as it does in Cacna1c +/+ mice indicates that DAT function is likely altered by Cacna1c haploinsufficiency in some way other than regulation of total DAT protein levels. Further studies are needed to determine how Cacna1c, which is localized mainly somatodendritically (Hell et al. 1993; Leitch et al. 2009 ), may alter terminal DAT function.
Reduced stimulant-induced slowed DA reuptake in Cacna1c haploinsufficient mice indicates that there may be an effect of reduced Cacna1c levels on stimulant-induced locomotor activity. While stimulant-induced locomotion is a rudimentary model of mania in rodents, it has been commonly used to assess mania-related behaviors owing to a lack of alternative measures (Einat & Manji 2006; Nestler & Hyman 2010; O'Donnell & Gould 2007) . We have previously shown that male Cacna1c haploinsufficient mice manifest a reduced hyperlocomotor response to acute and chronic amphetamine administration. While female Cacna1c haploinsufficient mice also manifest reduced stimulant-induced hyperlocomotion, baseline locomotor differences would confound our capacity to interpret results (Dao et al. 2010) . In the present study, we replicate our previous finding in male mice, as well as show that Cacna1c haploinsufficiency leads to an attenuated hyperlocomotor response to both acute and repeated administration of several psychostimulants. This suggests that reduced levels of Cacna1c likely represent a protective phenotype against mania-related behavior. While the dose of psychostimulants used in this study was selected to produce a moderate effect based on what has been published previously in the literature (Hirabayashi et al. 1991; Liljequist et al. 1991; McNamara et al. 2006; Young et al. 2010) , the use of only one dose of psychostimulant is a limitation. Previous studies have indicated that calcium influx through brain LTCCs is necessary for mediating psychostimulant-induced behavior and Cacna1c is particularly important in sensitization to psychostimulants. In rats, the calcium channel blocker flunarizine attenuated the increased Reduced Cacna1c attenuates MA-DL system function locomotor response induced by chronic cocaine administration (Mills et al. 2007 ) and nifedipine blocks expression of amphetamine-or cocaine-induced sensitization (Giordano et al. 2010) . Following sensitization to psychostimulants, LTCC-dependent calcium uptake increases (Mills et al. 2007 ) and signaling pathways downstream of Cacna1c are activated in the NAc (Giordano et al. 2010) .
The locomotor response to psychostimulants is largely mediated through the ML-DA pathway, although in the NAc, both DAergic and glutamatergic inputs are important for the psychostimulant-induced response (Vanderschuren & Kalivas 2000; Wolf & Khansa 1991) . Our finding that there was no attenuation of the hyperlocomotor response induced by the NMDA receptor antagonist MK-801 in Cacna1c +/− mice indicates that DA, rather than glutamate, system function is likely altered as a result of reduced Cacan1c. Previous studies support this conclusion, showing that LTCCs mediate cocaine-induced elevations of monoamine levels in terminal regions (Mills et al. 2007; Okita et al. 2000) .
In the present study, we further identified a role for Cacna1c in regions of the ML-DA circuit that underlie sensitization to GBR12909. While reduction of Cacna1c in the NAc was not sufficient to attenuate sensitization to GBR12909, we found that when Cacna1c was reduced in the VTA, sensitization above the initial acute response to GBR12909 was completely absent. This result suggests that Cacna1c in the VTA is essential for normal psychostimulant-induced sensitization. This finding is consistent with previous research, which has found that pharmacological blockade of LTCCs directly in the VTA blocks sensitization (Licata & Pierce 2003) , while activation of LTCCs augments sensitization (Licata et al. 2000) . Furthermore, sensitization leads to increased expression of Cacna1c mRNA and Ca v 1.2 protein in the VTA (Rajadhyaksha et al. 2004) . While Cacna1c does influence the downstream effects of psychostimulant exposure in the NAc, such as through increases in calcium uptake increases and activation of signaling pathways (Mills et al. 2007; Giordano et al. 2010) , blocking LTCCs exclusively in the NAc does not lead to attenuation of the psychostimulant-induced hyperlocomotion (Pierce et al. 1998) . Our findings, combined with those of previous studies and our own FSCV results, indicate that Cacna1c in the VTA may have a significant role in presynaptic regulation of the response to psychostimulants.
Our finding that selective reduction of Cacna1c levels in only the VTA or NAc did not modify acute locomotor responses to GBR12909 is consistent with previous studies that have found no acute locomotor response to cocaine following administration of an LTCC antagonist to the NAc (Karler et al. 1991; Pierce et al. 1998) . It is of interest to note the difference in response to chronic psychostimulant administration in haploinsufficient mice compared to mice with conditional knockdown of Cacna1c. In Cacna1c +/− mice, sensitization was reduced, but not completely blocked, as opposed to the complete lack of sensitized response when Cacna1c was selectively knocked down in the VTA. In Cacna1c +/− mice, the different outcome could be because of the involvement of reduced Cacna1c in additional circuits contributing to psychostimulant-induced behavior, or the constitutive nature of the knockout in Cacna1c +/− mice leading to compensatory mechanisms that modulate aspects of this behavior. In support of this, a low dose of nimodipine is sufficient to selectively block the maintenance of sensitization to GBR12909; however, when a higher level of LTCC blockade is present, the locomotor response is attenuated both acutely and during sensitization.
The results from this study show that when levels of Cacna1c are reduced, a potential protective phenotype against mania-or psychosis-related behavior emerges. In addition, these studies indicate that the attenuation of maniaor psychosis-related behavior following reduction of Cacna1c levels is due at least in part to altered terminal DA reuptake. As dysregulation of the DAergic system contributes to the etiology of mood disorders, the knowledge that Cacna1c is important for normal function of the ML-DA system has considerable implications for our understanding of how Cacna1c may confer risk. Additional studies are needed to further understand how DA reuptake is altered following sensitization to GBR12909, as well as the specific mechanism through which Cacna1c modifies DA reuptake. As the risk-associated SNPs identified in CACNA1C likely influence risk through altered levels of expression of CACNA1C (Bigos et al. 2010; Eckart et al. 2016; Gershon et al. 2014; Roussos et al. 2014; Yoshimizu et al. 2014) , these findings are important steps toward understanding the ramifications of altered expression in brain regions particularly relevant to psychiatric disorders.
